SynAct Pharma’s AP1189 meets primary endpoint and demonstrates favorable safety profile in Rheumatoid Arthritis patients with active joint disease in the Phase 2a BEGIN study
SynAct Pharma hosted an investor call November 30 at 15:00 CET to discuss the results from the Phase 2a BEGIN study and to discuss next steps for the company.
AP1189
A Novel and First-in-Class Agent to Target the Melanocortin System
Our lead drug candidate AP1189, a once-daily oral selective melanocortin agonist, specifically stimulates melanocortin receptors – a distinct mode of action compared to approved anti-inflammatory drugs which can be immunosuppressive. SynAct is currently evaluating AP1189 in rheumatoid arthritis (RA), in idiopathic membranous nephropathy (iMN, an autoimmune disease associated with the development of nephrotic syndrome) and in the treatment of respiratory insufficiency caused by COVID-19 infection.
-
January 7, 2022 Non RegulatorySynAct Pharma appoints Patrik Renblad as CFO
-
December 7, 2021 Non RegulatorySynAct Pharma’s board and management extend lock-up agreements
-
November 12, 2021 RegulatoryInterim report Q3 2021
-
August 27, 2021 RegulatorySynAct Pharma: Interim Report January-June 2021 August 27, 2021 (Q2 2021 Report included)
-
December 10, 2021SynAct discusses AP1189 with Sedermera
-
December 10, 2021MedWatch: Synact Pharma vil intensivere partner-drøftelser
A Management Team Committed to Success
An experienced team driven to help address areas of unmet therapeutic need while building value for shareholders. SynAct Pharma leads the emerging field of Resolution Therapy.